Navigation Links
AlphaRx Shareholder Update
Date:6/24/2009

MARKHAM, ON, June 24 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) releases letter to their shareholders:

Dear Shareholders,

We wanted to take a few minutes to update the current views on AlphaRx. For the first time in our corporate history, we ended our last quarter with a small profit. Aside from the fact that it was a small amount, it was significant on more than one front. The events that occurred over the past few weeks, have woke up investors around the world.

Our revenue is growing and our product pipeline remains robust and stronger than ever. We have 2 partnered products with potential milestone payments in excess of US$ 155 million which may generate a long-term stream of multi-million dollar royalty income. We at AlphaRx, have established research collaborations with leading specialty pharmaceutical companies and research institutions, such as the US Army. We have both benefited either financially or scientifically. Furthermore, these collaborations may lead to licensing agreements of our products.

We are in the forefront of nanomedicine development and we are poised to be the world's first pharmaceutical company to commercialize a polymeric-based nanomedicine for the treatment of nosocomial pneumonia.

Our goal, as it has been from Day number one, is to create profit for our shareholders and increase shareholder value. We believe we are succeeding. Thank you for your support. We will continue to keep you informed.

    Michael M. Lee

    President & CEO

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
2. AlphaRx Signs Cooperative Research and Development Agreement with US Army
3. AlphaRx Provides Corporate and Development Update
4. AlphaRxs Indaflex(TM) Continues its Clinical Development
5. AlphaRx CEO Accumulates More Company Shares
6. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
7. AlphaRx Announces Debt Conversion
8. AlphaRx To Present at 47th Annual ICAAC
9. All Seven Members of RBC Life Sciences Board of Directors Were Re-Elected During the Companys 2009 Annual Shareholders Meeting
10. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
11. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... , ... North Cypress Medical Center hosted its 9th Annual Spring ... the help of community partners, the event organizers raised $45,000 for the Lone ... members and their families through health, wellness, and therapeutic support. , A special ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management ... Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI ... member of the Institute for Functional Medicine. , He also heads up FITTLab, the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the ... bunionette) treatment was more than humbled by customer demand over the Mother’s Day Weekend ... mid sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack ... The Dough Bar, has ignited an undeniable buzz in the protein product community ... not just any doughnut.  These doughnuts are packed with 11 grams of protein and ...
(Date:5/26/2016)... ... 2016 , ... Metcalf & Associates’ Maureen Metcalf ... in leading technology and human resources operations for health care, education, banking, and ... featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders Driving Thriving Organizations. ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
Breaking Medicine Technology: